Clinical behavior of Streptococcus pneumoniae meningoencephalitis.
OBJECTIVE
There was an increased number of cases of meningoencephalitis caused by Streptococcus pneumoniae, after the successful vaccination campaigns against Neisseria meningitidis and Haemophilus influenzae. This paper aims at describing the clinical characteristics, the laboratory findings, the complications, and the therapeutic management of these patients, who have been suffering from this disease since 1993 to 2006.


METHODS
Twelve children with Streptococcus pneumoniae meningoencephalitis admitted to the pediatric hospital of San Miguel del Padron, City of Havana in this period were assessed.


RESULTS
Children under one year are the most frequently affected. Septic shock and brain edema were the most severe complications. Three patients died, implying that this disease has a serious course. Early treatment of brain edema is very important to reduce mortality. The elective drugs for treatment of these cases of Streptococcus pneumoniae meningoencephalitis were vancomycin combined with cephalosporin, cefotaxime or ceftriaxone type.


CONCLUSIONS
Patients with Streptococcus pneumoniae meningoencephalitis show clinical characteristics, complications, and sequels that are different to other bacterial meningoencephalitis, meaning that they could be helpful for physicians considering the differential diagnosis of meningoencephalitis.
Bu-Coifiu Fanego
Raisa
R
Central Laboratory for Cerebrospinal Fluid, Medical School Dr. Miguel Enríquez, Ciudad Habana, Cuba 11000.
Dorta-Contreras
Alberto J
AJ
Padilla-Docal
Bárbara
B
O'Farril-Sanchez
Martha
M
Lopez-Hernandez
Isabel
I
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002648:Child; D003430:Cross-Sectional Studies; D006801:Humans; D007223:Infant; D008590:Meningoencephalitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D011008:Pneumococcal Infections / Q000175:diagnosis* / Q000188:drug therapy; D011446:Prospective Studies; D013296:Streptococcus pneumoniae; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D014640:Vancomycin